ReviewCurrent protein & peptide science2026
Recent Advances in Antimicrobial Proteins and Peptides: A Promising Clinical Breakthrough and Patent Landscape.
Review in Current protein & peptide science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Antimicrobial resistance (AMR, when microbes stop responding to medicines) is a growing worldwide concern calling for novel alternatives to conventional antibiotics. Because of their wide range of efficacy, ability to support the body's natural defenses, and possible use in the treatment of cancer and inflammation-related illnesses, antimicrobial peptides (AMPs, short chains of amino acids that kill harmful microbes) and proteins stand out among these substitutes. In contrast to standard antibiotics, AMPs act against several cellular targets, making it harder for microbes to become drug-resistant. Despite challenges such as stability, scalability of production, and regulatory constraints, this review discusses recent progress in advancing the clinical utility of AMPs through synergistic approaches with approved drugs and sophisticated delivery systems. It highlights the strategic integration of biotechnological advancements with established AMP therapy, potentially providing efficient and cost-effective treatment options for infections that no longer respond to standard antibiotics. These trends position AMPs as next-generation therapeutics to address global health challenges.
Indexed as
Identifiers
42136483What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.